Healthcare / Drug Manufacturers - GeneralNYSE American
$3.34
-0.02 (-0.60%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-1.0M · quality 68.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
26/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$39M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-211.6%
↓Gross Margin
N/A
•Debt/Equity
0.04
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.84x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-5.9M · FCF $-4.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Net Income | $-5.9M | $-5.9M | $-1.5M | $-1.1M | $-1.7M |
| EBITDA | $-4.9M | $-4.9M | $-1.1M | $-1.1M | $-2.1M |
| EPS | -0.72 | -0.72 | -0.22 | -0.20 | -0.24 |
| Balance Sheet | |||||
| Debt/Equity | 0.04 | 0.04 | -0.56 | -0.65 | -0.56 |
| Current Ratio | 2.25 | 2.25 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-4.9M | $-4.9M | $-665000.00 | $-1.0M | $-1.2M |
| Returns | |||||
| ROE | -211.6% | -211.6% | 47.7% | 27.7% | 61.4% |
| Valuation | |||||
| P/B | 9.67 | 9.67 | — | — | — |
| Growth & Yield | |||||
| EPS Growth | -227.3% | -227.3% | -10.0% | 17.9% | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-59.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.22 → -0.72
Residual
-59.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.